Both genetic and pharmacologic CDK7 inhibition consistently demonstrated potent antiproliferative effects in five different HNSCC cell lines, showing approximately 10-fold lower IC50 than the CDK4/6 inhibitor palbociclib. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.